Objective:

To develop CAR-expressing astrocytes for targeted clearance of amyloid-β in Alzheimer’s disease models.

Key Findings:

• CAR-expressing astrocytes enhanced Aβ clearance in vitro.
• In mouse models, they reduced plaque burden and prevented Aβ accumulation.
• Different CAR designs produced distinct biological effects, affecting astrocytes and microglia differently.

Interpretation:

The CAR-expressing astrocytes represent a self-sustaining system for Aβ clearance, potentially reducing the need for repeated dosing compared to current therapies.

Limitations:

• Findings are based on in vitro and mouse model data.
• Further research is needed to assess safety and translation to human applications.

Conclusion:

CAR technologies show promise for treating Alzheimer’s disease and other neurodegenerative disorders as they evolve.